



PRESS RELEASE • PRESS RELEASE • PRESS RELEASE

NEOVACS RECEIVES PAYMENT OF €415K FROM OSEO FOR THE TRACKER PROGRAMME

Third milestone payment in the Tracker program for Rheumatoid Arthritis

Paris, May 13, 2013 – **NEOVACS (Alternext Paris : ALNEV)**, a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that it has received €414,839 from the French Innovation agency Oséo following achievement of a third milestone in early April, in accordance with the schedule agreed between the parties as part of the Tracker Project in rheumatoid arthritis (RA). The Oséo funding for the project totals €6.4 million for NEOVACS, of which €3.5 million have already been received (including the current payment).

“Reaching this third milestone shows the progress that has been made in the development of TNF-Kinoid in rheumatoid arthritis and the quality of the work of the teams involved. This new funding is excellent news as we head into the Phase IIb of TNF-Kinoid in RA, which is expected to start in mid 2013. These funds complement the funds raised in our last capital increase” commented Guy-Charles Fanneau de La Horie, C.E.O of NEOVACS.

NEOVACS is the project leader of Tracker, a programme aimed at developing a global therapeutic strategy for patients with RA. The most effective drugs currently available, anti-TNF monoclonal antibodies, often induce antibodies to the drug that lead to resistance and/or intolerance to the treatment, which consequently becomes ineffective and/or toxic. The objective of Tracker is to test the therapeutic solution developed by Neovacs involving active anti-TNF immunisation, and to validate the diagnostic and monitoring tools produced by the partner company in the program, Theradiag. The OSEO funding totals €7.9 million, with €6.4 million for Neovacs.

About Neovacs

Neovacs is a biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that run until at least 2026) Neovacs is focusing its development efforts on two active immunotherapies: TNF-Kinoid is being developed for the treatment of TNF-mediated autoimmune diseases such as rheumatoid arthritis and Crohn’s disease, whereas IFN α -Kinoid is being developed for the indication of lupus. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

For more information on Neovacs, visit www.neovacs.fr

Contacts**Press – ALIZE RP**

Caroline Carmagnol

+33 (0)1 42 68 86 43

caroline@alizerp.com

NEOVACS

Nathalie Trépo

+33 (0)1 53 10 93 00

ntrepo@neovacs.com

Investors - NewCap

Valentine Brouchet/Pierre Laurent

+ 33 (0) 1 44 71 94 93

neovacs@newcap.fr